Document:

Exhibit 10.02

 

SETTLEMENT AGREEMENT AND RELEASE

 

This SETTLEMENT AGREEMENT
AND RELEASE (“Agreement”) dated as of July 22, 2022 (“Effective Date”) by and between Scott Cohen (hereinafter
referred to as “Cohen” or “EMPLOYEE”) and The Greenrose Holding Company Inc., (“GREENROSE” or “Employer”).

 

WHEREAS, EMPLOYEE’S employment
with GREENROSE will end on July 28 2022 (“Employment End Date”).

 

NOW THEREFORE, EMPLOYEE and
GREENROSE enter into this Agreement as detailed below in exchange for the following agreed upon terms and conditions of EMPLOYEE’S
separation from employment with GREENROSE:

 

1. Equity
Grant. As consideration for entering into this Agreement, GREENROSE shall grant to Cohen on or before five (5) days following the
filing by GREENROSE of its Form 10-Q for Q2 2022, fifty thousand (50,000) fully vested options pursuant to the GREENROSE’S 2021
Equity Incentive Plan (the “Equity Plan”). The parties agree that the Equity Grant is consideration for the resolution
of any and all kind of claim Cohen may allege arising out of or related to employment, the Employment Agreement and/or the termination
of employment with Greenrose pursuant to the General Release as set forth herein. The parties further recognize that neither party acknowledges
any wrongdoing and that the Equity Grant and the other terms of this Agreement are consideration for the comprehensive resolution of
all claims, if any, between the parties.

 

0. Cohen
shall have the right to continue his health insurance provided that he timely elects continuation coverage pursuant to COBRA. Information
regarding COBRA will be sent separately to him.

 

1. General
Release and Covenant Not to Sue. In consideration for this Agreement and the promises and covenants set forth herein, Cohen , and
his heirs, attorneys, administrators, executors, personal representatives, beneficiaries, and assigns RELEASE and FOREVER DISCHARGE GREENROSE,
and its affiliates, predecessors, successors, parents, subsidiaries, divisions, assigns, officers, directors, shareholders/unitholders,
representatives, employees, former employees, attorneys, administrators, executors, beneficiaries, personal representatives, and agents,
(all collectively referred to as “GREENROSE RELEASEES”), from any and all claims, demands, obligations, liabilities, costs,
court costs, expenses, including attorneys’ fees, actions or causes of action which Cohen has, may have or which may hereafter accrue
to him, including but not limited to any claim or claims on account of or arising out of (i) his employment with GREENROSE ; (ii) his
separation from employment with GREENROSE; (iii) any and all matters pertaining to his treatment as an employee or the end of his employment
with GREENROSE, including, without being limited to, claims under the common law of contracts, the common law of defamation, the common
law of tortious interference with contracts, the common law of fraud, the Age Discrimination in Employment Act of 1967, Title VII of the
Civil Rights Act of 1964, the Civil Rights Act of 1991, the Rehabilitation Act of 1973, the Americans with Disabilities Act, the Employee
Retirement Income Security Act, New York State Human Rights Law, New York City Human Rights Law, and any other federal or state, city
or other local employment law, and all other city, state or federal laws, whether statutory or common law. Cohen covenants not to sue
the GREENROSE RELEASEES for any of these released claims.

 

     

     

    

 

Notwithstanding the foregoing,
this Agreement does not preclude (a) claims for breach of this Agreement; (b) claims for any acts that occur after the date this Agreement
is signed; (c) any rights or claims to vested benefits under any retirement plan or as otherwise explicitly referenced in this Agreement;
(d) any claims that may not be released by applicable law; (e) any right Cohen may have to file, cooperate or participate in any proceeding
before the EEOC, or a similar state agency except, however, Cohen waives any right to recover any monetary damages or awards in connection
with any such proceeding.

 

Cohen represents that, as of
the date he signs this Agreement, he has no workplace injuries or occupational diseases.

 

In consideration of for this
Agreement and the promises and covenants set forth herein, GREENROSE and its affiliates, predecessors, successors, parents, subsidiaries,
divisions, assigns, officers, directors, shareholders/unitholders, representatives, attorneys, administrators, executors, beneficiaries,
personal representatives, and agents (all collectively referred to as “GREENROSE RELEASORS”) RELEASE and FOREVER DISCHARGE
Cohen and his heirs, attorneys, administrators, executors, personal representatives and assigns (all collectively “Cohen Releasees”)
from any and all claims, demands, obligations, liabilities, costs, court costs, expenses, including attorneys’ fees, actions or
causes of action which GREENROSE RELEASORS has, may have or which may hereafter accrue to him, including but not limited to any claim
or claims on account of or arising out of (i) its employment of Cohen; (ii) its separation of Cohen from employment with GREENROSE; (iii)
any and all matters pertaining to Cohen’s conduct at GREENROSE, including, without being limited to, claims under the common law
of contracts, the common law of defamation, the common law of tortious interference with contracts, the common law of fraud, and any other
federal or state, city or other local employment law, and all other city, state or federal laws, whether statutory or common law. GREENROSE
covenants not to sue the Cohen Releasees for any of these released claims.

 

3. Release
Includes Unknown Claims. The parties understand and agree that the released claims are intended to and do include any and all claims
of every nature and kind whatsoever (whether known, unknown, suspected, or unsuspected), which they have or may have against the other
party and the other party’s releasees, individually or collectively.

 

4. Discharge
of Claims Under the Age Discrimination in Employment Act. Cohen hereby knowingly and voluntarily releases and forever discharges
and covenants not to sue each and all of the RELEASEES, collectively and severally, from any and all liability, claims, allegations,
and causes of action arising under the Age Discrimination in Employment Act of 1967, as amended (“ADEA”) which he, his’s
heirs, administrators, executors, personal representatives, beneficiaries, and assigns have or claim to have against RELEASEES.

 

5. Indemnification
of Cohen. To the fullest extent allowed by law, the Company and any successor organization, shall release and hold harmless and indemnify
Cohen, his executors, or administrators, during and thereafter (i) for any acts or decisions made while performing services for the Company,
(ii) against any and all judgments, penalties, fines, settlements and reasonable expenses (including attorneys’ fees) actually
incurred by Cohen in connection with any threatened, actual or completed action, suit or proceeding, whether civil, criminal, arbitral,
administrative or investigative, or any appeal in such action, suit or proceeding, to which Cohen was, is or is threatened to be made
a named defendant or respondent, because such person was an employee/officer of the Company, or was serving at the request of the Company
as an officer, trustee, employee, agent or similar functionary of another corporation, partnership, trust, employee benefit plan or other
enterprise. The Company herby affirms, that actions performed by Cohen, while performing services for the Company, were done at the direction
or knowledge of the Board of Directors and or Chief Executive Officer. This indemnification provision excludes indemnification for (i)
willful misconduct, (ii) gross negligence or (iii) fraud that Cohen knowingly or willingly committed.

 

    2

     

    

 

6. Non-Disclosure
of Proprietary or Confidential Information. Cohen understands that “Confidential Information” means any GREENROSE
proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products,
services, design, plans or proposals, identification of customer contact-persons, markets, software, developments, inventions, processes,
formulas, technology, drawings, engineering, hardware configuration information, marketing, finances, wages, employee information or
other business information disclosed to Cohen by GREENROSE either directly or indirectly in writing, orally or by drawings or observation
of plans, presentations, or documents. Cohen agrees, to hold in strictest confidence, and not to use, or to disclose to any person, firm
or corporation without written authorization of an officer of GREENROSE.

 

Nothing in this Agreement prohibits
Cohen from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information
to government agencies, filing a complaint with government agencies, or participating in government agency investigations or proceedings,
as required by applicable law. Cohen is not required to notify GREENROSE of any such communications; provided, however, that nothing herein
authorizes the disclosure of information Cohen obtained through a communication that was subject to the attorney-client privilege. Further,
notwithstanding Cohen’s confidentiality and nondisclosure obligations, Cohen is hereby advised as follows pursuant to the Defend
Trade Secrets Act: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for
the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly
or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is
made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files
a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the
individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade
secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.”

 

7.  Non-disparagement
and Confidentiality. In consideration of the Equity Grant set out in Section 1, Cohen also agrees not to make any disparaging remarks
in any form, including social media, about GREEENROSE, its business, owners, officers, managers, directors, employees, customers, agents,
representatives, shareholders/unitholders or subsidiaries.

 

GREENROSE agrees that its owners, officers, managers
and directors will not make any disparaging remarks in any form, including social media about Cohen. GREENROSE further agrees to respond
to inquiries from Cohen’s perspective employers by stating only (1) the dates of Cohen’s employment, (2) Cohen’s job
title, and (3) that it is GREENROSE policy to only share the foregoing information. This non-disparagement provision shall not in any
way prevent the parties from disclosing any information otherwise covered by this Section 7 to their attorneys, or pursuant to a lawful
subpoena or court order.

 

The parties promise and agree
not to discuss, disclose or divulge the terms, contents or existence of this Agreement to any person or entity, and further agree not
to show this Agreement to any person or entity, including, without limitation, the general public or the media. The parties may disclose
the terms of this Agreement to their financial, legal or tax advisors (each of whom shall be informed of this confidentiality provision
and agree to abide by it) and GREENROSE may further make similar disclosures to its management and its investors or prospective investors
provided such individuals or entities are obligated to abide by the terms of this provision. This provision also does not prevent the
disclosure of this Agreement as part of an action to enforce its terms. In the event the parties are asked any questions (other than pursuant
to a subpoena or court order) about the outcome or resolution of this matter, the parties shall state only that the parties have
resolved all matters and have separated amicably.

 

8. Company
Property. Cohen agrees that he shall promptly return to GREENROSE, and in any event shall do so no later than the Effective Date,
all property (including, without limitation, all keys, keycard, phone, and other access devices, all records, files, computer equipment
as well as any documents relating to GREENROSE business whether in hard copy or electronic and whether it is a formal or informal document
(such as notes or other records that he may have compiled that relate to GREENROSE or Releasees). Notwithstanding the foregoing the Company
acknowledges and agrees that Cohen may retain copies of certain email correspondence for his personal records. Upon receipt of such property,
the Company will acknowledge in writing to Cohen (i) receipt of such property (itemized as need) and (ii) Cohen’s compliance with
this Section 8.

 

    3

     

    

 

9. Other Matters.
(a) On the Employment End Date, Employee shall be paid any unpaid salary accrued through the date of such termination (including amounts
deferred by Cohen commencing July 1, 2022 through Employment End Date), and any outstanding expense reimbursements, which shall have
been incurred as of the Employment End Date. (b) On the Employment End Date or prior thereto, Cohen shall be removed from all offices,
boards, committees and any other offices or positions of the Company or its subsidiaries. (c) After the Employment End Date and until
August 7, 2022, Cohen will make himself available during typical business hours to respond to questions from Company representatives,
within a reasonable time period. (d) Following August 7, 2022, if mutually agreed to by the parties, the Company may engage Cohen for
certain post-employment services. The terms and conditions of any such engagement shall be set forth in a separate consulting services
agreement.

 

10. Cooperation.
Cohen agrees that, to the extent permitted by law, he shall cooperate fully with the Company in the investigation, defense or prosecution
of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against the Company
by a third party or by or on behalf of the Company against any third party, whether before a state or federal court, any state or federal
government agency, or a mediator or arbitrator. Your full cooperation in connection with such claims or actions shall include, but not
be limited to, being available to meet with the Company’s counsel, at reasonable times and locations designated by the Company,
to investigate or prepare the Company’s claims or defenses, to prepare for trial or discovery or an administrative hearing, mediation,
arbitration or other proceeding and to act as a witness when requested by the Company. Cohen further agrees that, to the extent permitted
by law, he will notify the Company promptly in the event that he is served with a subpoena (other than a subpoena issued by a government
agency), or in the event that he is asked to provide a third party (other than a government agency) with information concerning any actual
or potential complaint or claim against the Company. The Company agrees to compensate Cohen for his time at a rate of $650 per hour and
for actual out-of-pocket expenses, including legal fees, if any, involved in his cooperation, subject to Cohen providing to the Company
suitable evidence and documentary support. Any upfront legal fees, such as retainers will be advanced to Cohen at the time such fee becomes
due and payable.

 

11. Non-solicitation.
For twelve months following the Effective Date, Cohen will not, directly or indirectly) contact, solicit, induce or encourage any employee
or independent contractor of the Company or its subsidiaries or other person affiliated with the Company to curtail or terminate such
person’s affiliation or employment or retention, or take any action that results, or might reasonably be expected to result, in
any such person ceasing to perform services for the Company. Notwithstanding the foregoing, the restrictions on solicitation in this
Section 11 shall not preclude solicitations through the use of general advertising (such as web postings or advertisements in publications)
or search firms, employment agencies or similar entities not specifically directed at the Company or its subsidiaries.

 

12. Entire
Agreement. The provisions included in this Agreement constitute the entire agreement between GREENROSE and Cohen, and no other agreement
shall have any force or effect unless it is reduced to writing and signed by Cohen and an authorized official of GREENROSE.

 

13. New York
Law. This Agreement shall be interpreted and controlled by New York law.

 

14. Severability.
In the event any provision of this Agreement should be held to be unenforceable, each and all other provisions of this Agreement shall
remain in full force and effect.

 

15. Successors.
Each of the covenants and undertakings in this Agreement shall be binding upon and shall inure to the heirs, executors, administrators,
successors and assigns, respectively, of each of the parties.

 

16. Headings
and Captions. The headings and captions used in this Agreement are for convenience or reference only, and shall in no way define,
limit, expand or otherwise affect the meaning or instruction of any provisions of this Agreement.

 

17. Assignment.
This Agreement shall not be assignable by any party without the written consent of the others.

 

    4

     

    

 

I HAVE READ EVERYTHING IN THIS AGREEMENT AND
I UNDERSTAND EVERYTHING THAT IS IN THIS AGREEMENT. I UNDERSTAND THAT THIS AGREEMENT IS A CONTRACT AND A LEGAL DOCUMENT, AND THAT I SHOULD
TALK TO MY LAWYER ABOUT IT BEFORE SIGNING IT. I HEREBY STATE THAT I HAVE HAD ALL OF THE TIME I WANT AND NEED TO TALK TO A LAWYER ABOUT
THIS AGREEMENT BEFORE SIGNING IT. NO ONE HAS MADE ME ANY PROMISES TO GET ME TO SIGN THIS AGREEMENT EXCEPT FOR THE PROMISES THAT ARE WRITTEN
IN THIS AGREEMENT ITSELF. NO ONE HAS FORCED ME TO SIGN THIS AGREEMENT, AND I SIGN IT OF MY OWN FREE WILL.

 

	 	 
	 	Scott Cohen
	 	Date Signed: 7/22/2022
	 	 
	 	The Greenrose Holding Company Inc.

 

	 	By:	      
	 	Name: William Harley
	 	Title: CEO
	 	Date Signed:

 

 

5EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 PURCHASE
AGREEMENT 
 July 27, 2022 
 Artal International
S.C.A. 
 44 rue de la Vallée 
 L-2661 Luxembourg 
 Luxembourg 

Attention: Anne Goffard 
 The Invus Group, L.L.C. 

750 Lexington Avenue (30th Floor) 
 New York, New York 10022 

Attention: David van Zandt 
 Lexicon Pharmaceuticals, Inc. 

2445 Technology Forest Blvd., 11th Floor 

The Woodlands, Texas 77381 
 Attn: President and Chief
Executive Officer 
 Ladies and Gentlemen: 

Reference is made to (a) that certain Underwriting Agreement being entered into by Lexicon Pharmaceuticals, Inc. (the
“Company”) with the representatives of the underwriters named in Schedule II thereto (the “Underwriters”) concurrently with this Agreement (the “Underwriting Agreement”) providing for the issuance
by the Company to the Underwriters (the “Public Offering”) of 16,843,600 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), plus up to
2,526,540 additional shares of Common Stock (the “Option Shares”) that may be issued pursuant to the Underwriters’ option to purchase additional shares of Common Stock provided for in Section 2(b) of the Underwriting
Agreement (the “Option”), for sale in a public offering at a price to the public of $2.50 per share (the “Purchase Price”), (b) the Fifth Amended and Restated Certificate of Incorporation of the Company, dated
May 20, 2022 (the “Certificate of Incorporation”) and (c) the Registration Rights Agreement, dated as of June 17, 2007 (as amended, supplemented or otherwise modified, the “Registration Rights
Agreement”), by and between Invus, L.P. and the Company. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Underwriting Agreement. 

In consideration of the mutual covenants and agreements herein contained, and intending to be legally bound hereby, pursuant to
Section 12.01(c) of the Certificate of Incorporation and Section 2.02(a) of the Registration Rights Agreement, each of Artal International S.C.A. (the “Investor”), Artal Group S.A., Artal International Management S.A.,
Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Mr. Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A. (the “Invus Entities”), as applicable, hereby waives its rights under
(A) Section 12.01 of the Certificate of Incorporation to purchase the Firm Shares and Option Shares in connection with the Public Offering and (B) Section 2.02 of the Registration Rights Agreement the opportunity to include in
the Public Offering its Registrable Securities (as defined in the Registration Rights Agreement), and the Investor shall purchase, subject to the terms and conditions herein, (i) 16,173,800 shares of Common Stock (the “Firm Investor
Shares”) and (ii) in the event that the Underwriters exercise the Option, up to 2,426,070 shares of Common Stock (the “Option Investor Shares”). 

 

	I.	 The Firm Investor Shares 

Subject to the satisfaction or waiver of the conditions described in Section V, the Investor hereby agrees to purchase the Firm Investor
Shares from the Company at the Purchase Price. The total purchase price for the Firm Investor Shares shall be equal to $40,434,500. 
 The
closing of the sale of the Firm Investor Shares shall take place concurrently with the closing of the sale of the Firm Shares under the Underwriting Agreement (the “Firm Closing Date”), (i) with payment for the Firm Investor Shares
to be made to the Company by wire transfer of immediately available funds on the Firm Closing Date and (ii) with delivery of the Firm Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and
clear of all liens, with any transfer or stamp taxes duly paid by the Company. 

	II.	 The Option Investor Shares 

In the event that the Underwriters exercise the Option, the Investor shall have the option to purchase, at the Purchase Price, a number of
Option Investor Shares from the Company, determined by multiplying 2,426,070 by a fraction, the numerator of which shall be the number of Option Shares as to which the Underwriters exercise the Option and the denominator of which shall be the
maximum number of Option Shares subject to the Option, rounded down to the nearest whole number. 
 The closing of the sale of the Option
Investor Shares purchased pursuant to this Section II shall take place concurrently with the closing of the sale of the Option Shares, as to which the Underwriters exercise the Option (the “Option Closing Date”), (i) with payment
for the Option Investor Shares to be made to the Company by wire transfer of immediately available funds on the Option Closing Date and (ii) with delivery of the Option Investor Shares registered, as applicable, in the name of the Investor or
its designees and otherwise free and clear of all liens, with any transfer or stamp taxes duly paid by the Company. 
  

	III.	 Representations, Warranties and Covenants 

The Company hereby represents and warrants to and agrees with the Investor to all the same representations and warranties contained in
Section 1 and the covenants contained in Section 5 of the Underwriting Agreement mutatis mutandis to the same extent as if such representations and warranties and covenants were set forth herein for the benefit of the Investor
instead of the underwriters party to the Underwriting Agreement (except that references to the Underwriting Agreement therein shall be references to this Agreement and references to the Underwritten Securities and Option Securities thereunder shall
be references to the Firm Investor Shares and Option Investor Shares, respectively). 

  
 2 

 The Investor hereby represents and warrants to the Company that it (i) is acquiring the
securities to be purchased pursuant to this Agreement (the “Purchased Securities”) for its own account solely for the purpose of investment and not with a view to, or for resale in connection with, any distribution of such Purchased
Securities or any interest therein and (ii) has been provided an opportunity to ask questions of and receive answers from representatives of the Company concerning the terms and conditions of this Agreement and the purchase of the Purchased
Securities contemplated hereby. 
  

	IV.	 Additional Covenants of the Company 

Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company agrees to pay or
cause to be paid the reasonable fees and expenses of Simpson Thacher & Bartlett LLP, counsel to the Invus Entities, relating to the Public Offering and the transactions contemplated by this Agreement within 15 days of the submission of any
invoice with respect thereto. 
  

	V.	 Conditions to the Investor’s Obligations to Purchase the Purchased Securities

 The obligations of the Investor hereunder to purchase the Firm Investor Shares and the Option Investor Shares, as the
case may be, from the Company, and of the Company to sell the Firm Investor Shares and the Option Investor Shares, as the case may be, to the Investor, will be subject to the satisfaction or waiver of the following conditions on or prior to the Firm
Closing Date and the Option Closing Date, as the case may be: 
 (a) The satisfaction by the Company of the conditions set forth in
Section 6 of the Underwriting Agreement (other than clause (l) thereunder); 
 (b) The substantially concurrent closing of the
sale of the Firm Shares and the Option Shares, as the case may be, on the terms set forth in the Underwriting Agreement; 
 (c) The delivery
to the Investor of opinions of counsel to the Company by the same counsel as set forth in Sections 6(b), (c) and (d) of the Underwriting Agreement in the form and substance acceptable to the Investor; and 

(d) The delivery to the Investor of the officer’s certificate contemplated by Section 6(f) of the Underwriting Agreement. 

These conditions are for the Investor’s sole benefit and may be waived by the Investor in its sole discretion. 

 

	VI.	 Termination 

This Agreement shall automatically terminate upon any termination of the Underwriting Agreement. 

  
 3 

	VII.	 Miscellaneous 

(a) The Company hereby agrees to indemnify and hold harmless each of the Invus Entities and each of their respective affiliates, directors,
officers, agents and employees and each person, if any, who controls the Invus Entities within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the “Indemnitees”) from
and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or relating to any
of the transactions contemplated by this Agreement. For the avoidance of doubt and notwithstanding the foregoing, the Company shall not be obligated to indemnify and hold harmless the Indemnitees from and against any losses resulting from a decrease
in the trading price of their Common Stock. 
 (b) The provisions of Sections 13, 14, 17, 18 and 19 of the Underwriting Agreement are
incorporated herein by reference and shall apply to this Agreement mutatis mutandis. 
 (c) This Agreement may not be amended or
modified except by an instrument in writing signed by, or on behalf of, the parties hereto. 
 (d) This Agreement shall be deemed to satisfy
(i) any requirements of the Invus Entities, as applicable, to provide written notice to the Company in accordance with Section 12.03 of the Certificate of Incorporation in order to be considered a “Covered Stockholder”, (ii) the
Company’s obligations under the Certificate of Incorporation with respect to the delivery of a “Notice of Issuance” with respect to the Firm Shares and any Option Shares and (iii) the Company’s obligations under the
Registration Rights Agreement to provide written notice of the Public Offering, and shall, to the extent the Company issues and delivers the Firm Shares and any Option Shares as contemplated by this Agreement, constitute the Invus Entities’
waiver of rights pursuant to each of Section 12.01 of the Certificate of Incorporation and Section 2.02 of the Registration Rights Agreement, as applicable, with respect to the Firm Shares and the Option Shares. 

(e) This Agreement may be executed and delivered in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. 

(f) All notices and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon
receipt) by delivery in person, by fax, by electronic transmission, by a recognized overnight courier service or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at
such other address for a party as shall be specified in a notice given in accordance with this clause (f)): 
 if to any of
the Invus Entities: 
 Artal International S.C.A. 

44 rue de la Vallée 

L-2661 Luxembourg 

Luxembourg 

Attention: Anne Goffard 

and 

  
 4 

 The Invus Group, L.L.C. 

750 Lexington Avenue (30th Floor) 

New York, New York 10022 

Attention: David van Zandt 
 with
a copy to: 
 Simpson Thacher & Bartlett LLP 

425 Lexington Avenue 
 New York,
New York 10017 
 Attention: Kenneth Wallach, Esq. 

        Hui Lin, Esq. 

if to the Company: 
 Lexicon
Pharmaceuticals, Inc. 
 2445 Technology Forest Blvd., 11th Floor 

The Woodlands, Texas 77381 

Attention: President and Chief Executive Officer 

with a copy to: 

Vinson & Elkins L.L.P. 

845 Texas Avenue, Suite 4700 

Houston, Texas 77002-6760 

Attention: David Palmer Oelman, Esq. 

[Signature Page Follows] 

  
 5 

 
			
	Sincerely,
	
	 INVUS, L.P.,
 a Bermuda limited
partnership

		
	By:	 	Invus Advisors, L.L.C., its general partner
		
	By:	 	/s/ Philip Bafundo
	Name:	 	Philip Bafundo
	Title:	 	CFO of the General Partner
	
	ARTAL INTERNATIONAL S.C.A., a Luxembourg partnership limited by shares
		
	By:	 	Artal International Management S.A., its managing partner
		
	By:	 	/s/ Anne Goffard
	Name:	 	Anne Goffard
	Title:	 	Managing Director
	
	ARTAL GROUP S.A.
		
	By:	 	/s/ Anne Goffard
	Name:	 	Anne Goffard
	Title:	 	Déléguée à la gestion journalière
	
	ARTAL INTERNATIONAL MANAGEMENT S.A.
		
	By:	 	/s/ Anne Goffard
	Name:	 	Anne Goffard
	Title:	 	Managing Director
	
	INVUS ADVISORS, L.L.C.
		
	By:	 	/s/ Philip Bafundo
	Name:	 	Philip Bafundo
	Title:	 	Chief Financial Officer

 Signature Page to Purchase Agreement 

 
			
	INVUS PUBLIC EQUITIES, L.P.
	
	By: Invus Public Equities, LLC, its general partner
		
	By:	 	/s/ Philip Bafundo
	Name:	 	Philip Bafundo
	Title:	 	Chief Financial Officer
	
	AMAURY WITTOUCK
		
	By:	 	/s/ Amaury Wittouck
	
	STICHTING ADMINISTRATIEKANTOOR WESTEND
		
	By:	 	/s/ Amaury Wittouck
	Name:	 	Amaury Wittouck
	Title:	 	Sole Member of the Board
	
	WESTEND S.A.
		
	By:	 	/s/Anne Goffard
	Name:	 	Anne Goffard
	Title:	 	Managing Director

 Signature Page to Purchase Agreement 

			
	Accepted and agreed to:
	
	LEXICON PHARMACEUTICALS, INC., a Delaware corporation
		
	By:	 	/s/ Jeffrey L. Wade
	Name:	 	Jeffrey L. Wade
	Title:	 	President and Chief Financial Officer

 Signature Page to Purchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]